Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors' reply

Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498. doi: 10.1111/apt.16669.

Authors

Anne Flint¹, Grit Andersen², Paul Hockings^{3

4}, Leona Plum-Mörschel², Rohit Loomba⁵

Affiliations

¹ Novo Nordisk A/S, Søborg, Denmark.
² Profil, Neuss, Germany.
³ Antaros Medical, BioVenture Hub, Mölndal, Sweden.
⁴ MedTech West, Chalmers University of Technology, Gothenburg, Sweden.
⁵ University of California San Diego School of Medicine, San Diego, California, USA.

PMID: 34741327
DOI: 10.1111/apt.16669

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus*
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use
Non-alcoholic Fatty Liver Disease* / drug therapy
Obesity / complications
Obesity / drug therapy

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents